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Abstract 
 
Current anti-seizure therapy is ineffective in approximately one-third of people with epilepsy and is 
often associated with substantial side effects. In addition, most current therapeutic paradigms offer 
treatment, but not cure, and no therapies are able to modify the underlying disease, that is can prevent 
or halt the process of epileptogenesis or alleviate the cognitive and psychiatric comorbidities. 
Preclinical research in the field of epilepsy has been extensive, but unfortunately, not all the animal 
models being used have been validated for their predictive value. The overall goal of TASK 2 of the 
AES/ILAE Translational Task Force is to organize and coordinate systematic reviews on selected 
topics regarding animal research in epilepsy. Here we describe our strategy. In the first part of the 
paper we provide an overview of the usefulness of systematic reviews and meta-analysis for preclinical 
research and explain the essentials for their conduct. Then, we describe in detail the protocol for a first 
systematic review, which will focus on the identification and characterization of outcome measures 
reported in animal models of epilepsy. The specific goals of this study are to define systematically the 
phenotypic characteristics of the most commonly used animal models, and to effectively compare 
these with the manifestations of human epilepsy. This will provide epilepsy researchers with detailed 
information on the strengths and weaknesses of epilepsy models, facilitating their refinement and the 
future research. Ultimately, this could lead to a refined use of relevant models for understanding the 
mechanism(s) of the epilepsies and developing novel therapies.  
 
Key Words 
Systematic reviews, Meta-analysis, Animal models  
 
Key Point Box 
 Systematic reviews provide a scientific approach to the collection, grading and interpretation of 
large volumes of data. 
 A goal of the AES/ILAE Translational Task Force is to organize and coordinate systematic reviews 
regarding animal research in epilepsy. 
 The first systematic review will focus on the characterization of outcome measures reported in 
animal models of epilepsy. 
 This article describes in detail the protocol for this systematic review. 
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Introduction: systematic reviews and meta-analyses 
 
Historically, the medium of scientific communication limited the access of researchers to data. Now 
the opposite holds: the internet and electronic citation repositories allow access to huge amounts of 
data that in most circumstances cannot be assimilated by a single individual. As each scientist has to be 
extremely selective in their reading, there is a high risk of acquisition bias.  Moreover, the statistical 
power of single studies in basic and preclinical research is very often insufficient to draw solid 
conclusions, which may therefore be either falsely positive or negative. False negatives mean 
potentially valuable lines of research are shut down prematurely while false positives inflate our 
appreciation of the effect size.1; 2 Widespread publication bias can also lead to a false impression of the 
potential value of an area of research.3 This is especially so because positive results are more likely to 
be published in high impact journals and high impact journals are, by definition, more likely to be 
cited.   
 These problems have been addressed in clinical research by means of systematic reviews of the 
literature and meta-analysis of the data (Figure 1). Systematic reviews provide a scientific approach to 
the collection, grading and interpretation of large volumes of data. Detailing the search strategy used 
to explore the literature and defining inclusion and exclusion criteria allows readers to judge for 
themselves whether the writers have taken a rigorous approach to finding relevant data, providing a 
critical element of science: a defined methodology which allows others to confirm and extend the 
results. Meta-analysis allows aggregating and re-analyzing the data from systematic reviews. This can 
provide greater statistical power, leading to the discovery of effects that were not evident within single 
data sets, and can lessen the risk of chance associations (false positives).  
 In basic and preclinical research, the breadth of available data and heterogeneity of study design 
necessitate a different approach to the systematic review and meta-analysis process employed in 
clinical science. Assessments of risk of bias and estimation of the effect size for a single intervention 
can still be made, but the heterogeneity of design also facilitates study of the methodologies employed 
to model disease and of the underlying biological variables that influence outcome.4-10  
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Conduct of systematic reviews and meta-analyses on animal research 
 
Protocol. The prospective registration of protocols is recognized as an important part of the conduct of 
systematic reviews in the clinical sciences. Establishing a protocol for the research we intend to 
conduct serves a number of important functions that reduce waste and minimizes the risk of biases. If 
protocols are registered in an open database, potential authors can determine if another group has 
already initiated a systematic review on the same topic and decide whether to proceed with their 
review. Prospective registration also minimizes the potential for publication bias by maintaining a 
permanent record of initiated reviews, regardless of publication status. Finally, by describing a priori 
the analyses to be performed, a protocol protects against “HARKing” (Hypothesizing After Results are 
Known). In this regard, PROSPERO (http://www.crd.york.ac.uk/PROSPERO/) is an international 
prospective registry for systematic review protocols in human health. Expanding PROSPERO's scope 
to include systematic reviews of preclinical studies will provide authors with a central source for 
registering and searching for protocols. In addition to such registration it is appropriate for protocols to 
be published in peer-reviewed journals to provide more details on the background/rationale and 
methods.  
 
Search strategy. A comprehensive search strategy is essential to identify all studies relevant to a 
particular topic. The first steps in designing a comprehensive search strategy are: (i) translating the 
review questions into clear and simple ones, (ii) defining search components and (iii) building 
comprehensive search strategies which identify intersections of search components. SYRCLE 
(https://www.radboudumc.nl/Research/Organisationofresearch/Departments/cdl/SYRCLE/Pages/defau
lt.aspx) has developed several tools to specifically facilitate the search process for animal-based 
studies.11-13 
One of the greatest challenges in designing a comprehensive search is to find the right balance 
between sensitivity and specificity. Sensitivity is the proportion of relevant articles identified by a 
search strategy as a percentage of all relevant articles on a given topic. It is a measure of the ability of 
a search strategy to identify all relevant articles. Specificity is the proportion of relevant articles 
identified by a search strategy as a percentage of all articles (relevant and irrelevant) identified by that 
search. In other words, it is a measure of the ability of a search strategy to exclude irrelevant articles. 
Searches with a high sensitivity often result in relatively low specificity and vice versa. To increase 
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sensitivity of the search, the Cochrane handbook for systematic reviews of interventions 14 suggests 
using multiple databases in a search. However, while clinical researchers have begun to grapple with 
the issues of coverage of different databases,15-18 very little is known about the effect of search 
strategy, and database selection in particular, on the validity of systematic reviews in the context of 
animal studies.19  
 
Approaches to statistical analysis. Different approaches can be used to pool data from individual 
studies and provide summary estimates of effect. While the fundamental principles are the same as for 
meta-analyses of human clinical trial data, some important differences have to be considered in animal 
research. Clinical research reviews are usually based on a small number of studies involving large 
cohorts of patients, investigating a fairly homogenous treatment effect. In contrast, animal research 
reviews often involve a large number of studies, each with a small number of cases and, in general, 
with substantial heterogeneity in the circumstances of  testing (species, dose, timing of treatment, 
outcome assessed). While the purpose of clinical meta-analyses is usually to produce a better estimate 
of the treatment effect, such an estimate (e.g., improvement of drug outcome in a particular disease) has 
generally little meaning in animal studies. Rather, what is important are the associations between 
different aspects of experimental design and the observed effects, which might define the limits to 
efficacy; circumstances in which efficacy is not observed; the prevalence and impact of publication 
bias; and the impact of reporting of other risks of bias. Such an approach helps to define the reaction 
norms of the biological response. 
Effect size may be represented as (i) a mean difference (i.e., all outcomes use the same scale); 
(ii) a standardized mean difference (i.e., the effect is scaled according to the observed variance); (iii) a 
normalized mean difference (i.e., the effect is scaled as a proportionate improvement in outcome). 
Because animal studies rarely use the same scale and because the observed variance is an imprecise 
measure of the population variance, a normalized mean difference (NMD) approach is often used. 
When this is not possible, analyses based on standardized mean difference (SMD) can be used, but 
have lower statistical power because of the measurement error in the estimation of effect sizes.  
Sources of heterogeneity between different studies may be assessed through partitioning of the 
observed heterogeneity (i.e., the weighted sum of the squared deviations from the fixed effects 
estimate) into that occurring within groups and that occurring between groups. Alternatively, meta-
regression seeks to build a univariate or multivariate regression equation, which minimizes the 
weighted squared deviations from the model. While both of these approaches have strengths, modeling 
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suggests  that partitioning of heterogeneity is much less conservative, in statistical terms, than meta-
regression (http://www.dcn.ed.ac.uk/camarades/files/CAMARADES%20Monograph%201.pdf). 
In this project we will use the partitioning of heterogeneity to summarize SMD effect sizes and 
metaregression when NMD effect sizes are used.  
 
Publication standards and meta-bias. As with any type of research, systematic reviews and meta-
analyses are susceptible to bias. It was found in a systematic review of systematic reviews of 
preclinical studies that 30% specified a testable hypothesis, 27% performed a literature search without 
language restrictions, 17% assessed for the presence of publication bias, 50% assessed study validity, 
and 2% investigated sources of heterogeneity.20 It is only through clear reporting of what was done 
that it is possible to assess the risk of bias. The potential users of the systematic reviews need to be 
able to assess whether the methodologies are sound and interpretations valid.  
 
 
 
 
 
Protocol for a systematic review on animal research in epilepsy  
 
There are many different topics of interest in pre-clinical epilepsy research, which are worthy subjects 
for systematic reviews and meta-analysis. As a start, our working group agreed that it would be 
relevant to identify and characterize the outcome measures that are the most frequently used to 
evaluate outcome in animal models of epilepsy. These are amongst the most important “tools of our 
trade” and it is critical to how they behave in different models of our disease and to understand which 
are fit for the task. This broad analysis will provide the foundations for more sharply focused reviews. 
Once we know which of our assessment tools are effective we can more effectively probe the 
relevance of our broad range of epilepsy and seizure models and the relative merits of individual 
corrective drugs. 
 Below, we provide a detailed protocol of this initial work, that has already been registered in 
the CAMARADES website 
(http://www.dcn.ed.ac.uk/camarades/files/epilepsy%20models%20protocol%20final.pdf). 
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Background  
 
Epilepsy is one of the most common neurological diseases. It affects an estimated 1% of the 
population, i.e. over 50 million individuals worldwide. Approximately one in 25 people will develop 
epilepsy at some point in their lifetime and it is estimated that 2.4 million people are newly diagnosed 
with epilepsy each year (http://www.who.int/mediacentre/factsheets/fs999/en/).21 In addition, 
neurological and psychiatric comorbidities heavily contribute to the disability of this population of 
patients. Since the introduction of the bromides as an anti-seizure drug almost two centuries ago, many 
effective therapies have been tested and introduced in clinical practice. These treatments have been 
referred to as ‘‘antiepileptic drugs’’ (AEDs), and about 20 of them have been developed during the last 
30 years. However, all AEDs are symptomatic agents that, at best, control the most obvious 
manifestation of the disease, i.e. seizures. For this reason, the term “anti-seizure drugs” (ASDs) is now 
preferred.22  However, seizures are still not adequately controlled in a third of the cases, ASDs often 
have side effects and no disease-modifying therapies (which remove the susceptibility to seizures) are 
yet available. Moreover, there are no therapies that specifically address the comorbidities of epilepsy. 
Therefore, an urgent demand exists to address these unmet clinical needs.23; 24 
 Preclinical research in epilepsy has strongly facilitated the discovery of ASDs with different 
mechanisms of action. Traditionally, these new therapies have been identified based on effects in 
preventing chemically (pentylenetetrazol, PTZ) or electrically (maximal electroshock, MES) induced 
acute seizures in otherwise normal animals or, more recently, in slowing kindling progression or 
increasing seizure threshold in fully kindled animals. These tests have been performed by individual 
research teams, by companies, or by the Epilepsy Therapy Screening Program (previously named the 
Anticonvulsant Screening Program, ASP), an initiative of the National Institute for Neurological 
Diseases and Stroke (NINDS). Some of the new ASDs introduced to the clinic as a result of this 
approach proved more tolerable, but the percentage of patients with drug-resistant epilepsy has not 
changed, nor have these new drugs proved effective in preventing epilepsy development in at-risk 
individuals or in treating co-morbidities.25 Probably because testing for tolerability and safety has been 
done in acute (and not chronic) epilepsy models, current screening methods have often failed to 
elucidate which drugs will produce significant adverse effects. Additional models (such as 6 Hz and 
status epilepticus models) have been proposed as additions to the screening, but these have not been yet 
fully validated for their predictiveness of therapeutic effects in human disease.24 In addition, the 
  8 
similarities of their characteristics with the human symptoms (i.e., their face validity) has been 
questioned.26; 27 
In summary, despite its important achievements, epilepsy therapy development still needs to 
address major existing unmet clinical gaps. To meet these demands, redesign of current translational 
approaches is needed.  The aims of this systematic review are to define the phenotypic features of some 
commonly used models, in order to effectively compare these to the aspects of the human clinical 
condition they are intended to model. This will provide epilepsy researchers with detailed information 
of the most commonly used models for future research and also give ideas on how the existing models 
could be improved. Ultimately, this could lead to a refined use of relevant models for understanding the 
mechanism(s) of the epilepsies and identifying novel therapies. To achieve these goals, (1) we created a 
list of animal models of induced epilepsy (Table 1) based on a report of the United Kingdom’s 
National Centre for Replacement, Refinement and Reduction of Animals in Research (NC3Rs) 
epilepsy working group28 and on a preliminary screening of the literature run by the authors; the list 
will be further refined following a more detailed screening to identify how many articles are published 
per model and select a more limited group of representative models to examine in detail; (2) we 
identified relevant outcome measures that would allow ascertainment of the impact of therapeutic 
interventions (Table 2). 
 
Objectives of the Systematic Review and Meta-Analysis 
 
As described above, animal studies have been instrumental in the identification of new effective ASDs. 
The species that proved most useful in this respect were small rodents (mice and rats), but much 
valuable data has also been obtained in other species ranging from fish (zebrafish) to primates. In this 
study, we will collect and examine results obtained in mammalian species. Non-mammalian species 
will be excluded only because the phenotypical presentation of the disease in these species is far less 
complex than in humans, preventing an in-depth comparison.  
Acquired epilepsies in humans are often caused by an initial epileptogenic insult (head trauma, 
episode of status epilepticus, stroke, brain infection, hyperthermia) that, after a latency period, may 
lead to the occurrence of spontaneous seizures and the diagnosis of epilepsy. All these epileptogenic 
insults can be reproduced in animals and, as in humans, may lead to spontaneous seizures after a 
latency period. Therefore, in this study we will consider all interventions intended by the authors to 
evoke acquired epilepsy. Interventions intended to induce a single seizure only will not be included. 
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Since this is not a therapeutic intervention, we will use here the term “epileptogenic insult”. Data from 
animals not receiving the epileptogenic insult (sham-animals or animals receiving vehicle rather than 
epileptogenic drug or insult) will serve as the control population.  We will categorize all reported 
outcomes as electrophysiological (EEG), behavioral, histological or imaging. Detailed analysis will 
focus on specific outcome measures selected on the basis of a survey among preclinical and clinical 
epilepsy experts (Table 2). The definitions and classifications of seizures are currently being developed 
by the TASK 1 of the AES/ILAE Translational Task Force, and are reported in detail in other articles 
of this supplement.  
Specifically, our research questions are: (1) What outcome measures are commonly reported in 
animal experiments modeling epilepsy? (2) To what extent do the changes associated with model 
induction reflect human epilepsy (face validity)? (3) What is the statistical performance (power to 
detect a given effect size) of different outcome measures, and does this differ between models? 
The protocol below describes the methodology we plan to use to pursue an answer to these questions. 
 
Methods  
 
Search strategy  
Databases to search. Based on previous experience, we chose to search Pubmed and Embase 
databases.  
Electronic search strategies. We will run the following search: [animal study string 12; 13 AND [all 
chronic models (named one by one)] AND [epilepsy]. The animal study strings are reported in the 
Appendix. 
 
Study selection procedures  
Screening phases. Pubmed and Embase search results will be downloaded to EndNote, and full text of 
articles retrieved when available using the automated EndNote feature (not available articles will be 
obtained via interlibrary loan or direct contact with authors). Unique results will be exported from 
Endnote as an XML file and uploaded into the SyRF application (http://app.syrf.org.uk/). Screening for 
inclusion/exclusion of titles and abstracts will be performed against the criteria below. Publications 
passing stage 1 will proceed to stage 2 according to the criteria below. The SyRF application allows 
that each screener is offered each record only once; and records are offered for screening until 2 
reviewers agree on disposal (inclusion or exclusion).  
  10 
 
 
 
Study selection criteria  
Inclusion and exclusion criteria. Inclusion: controlled studies comparing outcomes between a group of 
animals in which the epileptogenic insult has been induced and a group of animals not receiving that 
epileptogenic insult. Exclusion: acute seizure models; studies on transgenic and knockout mice; drug 
efficacy studies where outcomes are compared only in cohorts which have received an intervention 
intended to model epilepsy (no non-epileptic control); publications that do not contain primary data 
(i.e. review articles).  
Type of intervention. Any epileptogenic insult intended to induce a model of epilepsy (i.e. chronically 
reduced seizure threshold or induce spontaneous recurrent seizures or both). 
Language restrictions. Only papers in English. 
Publication date restrictions. None. 
Exclusion criteria per selection phase. Stage 1. This will be a screening phase based only on title and 
abstract. Inclusion criteria: i) papers written in English; ii) concerning the induced epilepsy models 
listed in Table 1; iii) using mammalian species. Exclusion criteria: i) paper not written in English; ii) 
not concerning the induced epilepsy models listed in Table 2; iii) using non-mammalian species.  
Stage 2. This will be the extraction phase, in which information will be extracted from the full text. The 
outcome measure and the mode of information extraction are listed in Table 2 and below (“Study 
characteristics to be extracted”). The reason for an extensive list of outcomes in Table 2 is proposed in 
an attempt to reduce a priori preconceptions of what outcomes are important, and we will employ 
statistical methods to account for multiplicity of comparisons.  
 
Study characteristics to be extracted   
All study characteristics will be extracted by two independent reviewers with discrepancies resolved by 
a third reviewer.  
Study ID. Unique Study identifiers will be generated automatically for each article and will be linked to 
the basic information of the publication extracted from the online searching engines.  
Study design characteristics (e.g. experimental groups, number of animals). Number of animals per 
experiment and per experimental cohort. 
Animal model characteristics. For each experiment, and for each experimental cohort: 
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1. species, strain and where available breeder; 
2. gender; 
3. age (or weight as a surrogate if age is not given); 
4. housing (singly- vs. group-housed).  
Intervention characteristics. For each experiment, and for each experimental cohort: 
1. method of induction of epilepsy; 
2. timing, and, when appropriate, number and intensity of induction events (i.e. drug dose, 
electrical stimulation parameters, amount of infective agent, etc.). 
Outcome measures. For each experiment: 
1. category of outcome measure (see Table 2); 
2. timing(s) of outcome assessment. 
For each experimental cohort: 
1. median or mean outcome at each time point; 
2. variance or IQR of mean or median outcome. 
 
Assessment risk of bias (internal validity) or study quality  
Number of reviewers assessing the risk of bias/study quality in each study and resolution of 
discrepancies. Two reviewers will be assigned to assess the risk of bias and study quality. 
Discrepancies will be resolved by a third screener.  
Criteria to assess the internal validity of included studies and/or other study quality measures. The 
study quality checklist described by CAMARADES29 study will be adapted as follows:  
 publication in peer-reviewed journal;  
 random allocation to group; 
 blinded conduct of the experiment; 
 blinded assessment of outcome; 
 sample size calculation; 
 reporting of animals excluded from analysis and reasons for exclusion (e.g. health status, 
general conditions or other parameters); 
 reported health status & general condition; 
 monitoring duration longer than 1 week (for adult animal models); 
 continuous (vs. discontinuous) monitoring (for adult animal models); 
 video-EEG monitoring; 
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 information about the course of spontaneous recurrent seizures (i.e. progression / regression / 
remission). 
 
 
Collection of outcome data  
Type of data to be extracted for each outcome measure. See Table 2. 
Methods for data extraction/retrieval. Multi-modal: 
1. from text;  
2. from graphs using a digital ruler software. 
 
Data analysis and synthesis  
How will data be combined/compared. Meta-analysis. 
How it will be decided whether a meta-analysis will be performed. Meta-analysis will be performed 
where more than 10 experimental comparisons are available. 
Effect measure. For dichotomous outcomes we will present odds ratios. For continuous outcomes we 
will use standardized mean difference. 
Statistical model of analysis. Random effects meta-analysis. 
Statistical methods to assess heterogeneity. I2 and Q. 
Which study characteristics will be examined as potential source of heterogeneity (subgroup analysis).  
Species; age at intervention; gender; housing (single vs. group; enrichment); time to outcome 
assessment; randomization, blinding. 
Sensitivity analyses. Meta-regression. 
Other meta-analysis details. To adjust for multiple testing of study design (n=4) and risk of bias (n=5) 
items we will use a Bonferroni-Holm correction. 
Method to assess for risk of publication bias. Risk of publication bias analyses will be assessed using 
funnel plot assessment and Egger’s regression. Trim and fill analysis will be used to assess the 
potential impact of publication bias. 
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Concluding remarks 
 
As stated, we expect that the protocol outlined in this article will lead to a series of systematic reviews 
and meta-analyses on preclinical epilepsy research. Once we have completed the analysis on the 
general features of the models and of their similarities to the human epilepsy condition, the following 
obvious step will be to analyze the effects of FDA- and EMA-approved drugs using the same approach. 
 This study is expected to provide concrete evidence to inform attempts to improve the currently 
available models of chronic epilepsy and the conduct of preclinical epilepsy research. In addition, we 
believe that this will help providing a more realistic and translationally useable view of the data 
generated by preclinical epilepsy research, identifying areas that need further exploration and providing 
more solid bases for the initiation and design of clinical studies.  
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Tables 
 
Table 1. Models of induced epilepsy 
 
  
Electrical  Chemical  Physical 
Electrically-induced status 
epilepticus (amygdala 
stimulation, perforant path 
stimulation) 
Pilocarpine 
Lithium-pilocarpine 
Traumatic brain injury (fluid 
percussion, controlled cortical 
impact) 
Penetrating brain injury 
Kindling (corneal, 
hippocampal, amygdaloidal, 
PTZ) 
Kainic acid (intraamygdala, 
intrahippocampal, 
intracerebroventricular, 
intraperitoneal, 
subcutaneous) 
Hypoxia  
Hypoxic-ischemic 
encephalopathy 
Hyperthermia 
 Tetanus toxin 
Osmotic blood-brain barrier 
disruption 
 Bicuculline intrahippocampal Stroke 
 Penicillin cortical Albumin 
 
Ferric salts (intraamygdala or 
intraneocortex) 
Prenatal teratogen, maternal 
stress and teratogen model 
of autism and epilepsy 
 Cobalt cortical 
Neurocysticercosis 
Viral encephalitis (Theiler's 
murine encephalomyelitis virus 
model) 
Multiple hit model of infantile 
spasms 
Tetrodotoxin model of spasm 
Undercut 
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Table 2. Outcome measures 
 
  
Outcome Scale Measure 
   
EEG 
Percent of tested animals with seizures Ordinal  Quantitative measure: % 
Frequency of spontaneous seizures Ordinal Quantitative measure: seizures/day 
Duration of spontaneous seizures 
Cumulative duration of seizure per EEG  
session (time spent seizing) 
Ordinal Quantitative measure: sec 
Frequency of interictal spikes Dichotomous 
Qualitative measure: yes/no (just note 
if evaluated in the paper) 
High frequency oscillations Dichotomous 
Qualitative measure: yes/no (just note 
if evaluated in the paper) 
Seizure threshold Dichotomous 
Qualitative measure: yes/no (just note 
if evaluated in the paper) 
Seizure spread Dichotomous 
Qualitative measure: yes/no (just note 
if evaluated in the paper) 
Behavior - seizures 
Percent of tested animals with seizures Ordinal Quantitative measure: % 
Semiology of seizures (different types) Dichotomous 
Qualitative measure: yes/no (just note 
if evaluated in the paper) 
Frequency of convulsive seizures Ordinal Quantitative measure: seizures/day 
Duration of convulsive seizures Ordinal Quantitative measure: sec 
Severity of convulsive seizures Nominal 
Quantitative measure: Racine scale 
(specify the Racine scale variant 
employed in the study) 
Post-ictal behavior (e.g. postictal 
depression or alterations in behavior 
following seizures) 
Dichotomous 
Qualitative measure: yes/no (just note 
if evaluated in the paper) 
Seizure threshold Dichotomous 
Qualitative measure: yes/no (just note 
if evaluated in the paper) 
Behavior - co-morbidities 
Anxiety- and depression-associated behavior 
Open field Ordinal 
Quantitative measure: entries in the 
central quadrants (number/min).  
Elevated plus maze Ordinal 
Quantitative measure: entries in the 
open arms (number/min). 
T maze Ordinal 
Quantitative measure: number of 
correct choices (% correct). 
Forced swimming Ordinal 
Quantitative measure: immobility (% 
total time of observation). 
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Light/dark (black/white) box Dichotomous 
Qualitative measure: yes/no (just note 
if evaluated in the paper) 
Glucose preference Dichotomous 
Qualitative measure: yes/no (just note 
if evaluated in the paper) 
Weight change Ordinal 
Quantitative measure: weight gain per 
week. 
Cognitive impairment 
Novel object recognition Ordinal 
Quantitative measure: % time 
exploring novel object. 
Morris water maze Ordinal 
Quantitative measure: % time in target 
quadrant in the probe trial. 
Barnes Maze Dichotomous 
Qualitative measure: yes/no (just note 
if evaluated in the paper) 
Nesting behavior Dichotomous 
Qualitative measure: yes/no (just note 
if evaluated in the paper) 
Autism 
Ultrasonic vocalization (USV)  Dichotomous 
Qualitative measure: yes/no (just note 
if evaluated in the paper) 
Social exploration/interaction Dichotomous 
Qualitative measure: yes/no (just note 
if evaluated in the paper) 
Repetitive behavior Dichotomous 
Qualitative measure: yes/no (just note 
if evaluated in the paper) 
Sleep impairment 
Sleep EEG Dichotomous 
Qualitative measure: yes/no (just note 
if evaluated in the paper) 
Histological 
Cell death 
Hippocampal volume Ordinal 
Quantitative measure: % control 
volume. 
Cell counting Dichotomous 
Qualitative measure: yes/no (just note 
if evaluated in the paper) 
Neuronal loss Dichotomous 
Qualitative measure: yes/no (just note 
if evaluated in the paper) 
Fluoro-Jade Dichotomous 
Qualitative measure: yes/no (just note 
if evaluated in the paper) 
TUNEL Dichotomous 
Qualitative measure: yes/no (just note 
if evaluated in the paper) 
Neurogenesis 
BrDU, Ki67, etc Dichotomous 
Qualitative measure: yes/no (just note 
if evaluated in the paper) 
Gliosis 
GFAP Dichotomous 
Qualitative measure: yes/no (just note 
if evaluated in the paper) 
Microgliosis 
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Iba1, Cd11b Dichotomous 
Qualitative measure: yes/no (just note 
if evaluated in the paper) 
Neuroinflammation 
Cytokines, cyclooxygenase-2, …  Dichotomous 
Qualitative measure: yes/no (just note 
if evaluated in the paper) 
Alterations in organization and morphology 
Granule cell dispersion  Dichotomous 
Qualitative measure: yes/no (just note 
if evaluated in the paper) 
Sprouting of the mossy fibers (Timm, 
ZnT3, dynorphin) 
Dichotomous 
Qualitative measure: yes/no (just note 
if evaluated in the paper) 
Alterations in dendritic arborization Dichotomous 
Qualitative measure: yes/no (just note 
if evaluated in the paper) 
Blood-brain barrier integrity 
Albumin, IgG, …  Dichotomous 
Qualitative measure: yes/no (just note 
if evaluated in the paper) 
Imaging 
MRI Dichotomous 
Qualitative measure: yes/no (just note 
if evaluated in the paper) 
PET Dichotomous 
Qualitative measure: yes/no (just note 
if evaluated in the paper) 
 
 
  
  21 
 
List of abbreviations 
 
AED, antiepileptic drugs 
ASD, anti-seizure drugs 
MES, maximal electroshock  
NMD, normalized mean difference 
PTZ, pentylenetetrazol 
SMD, standardized mean difference 
USV, ultrasonic vocalization 
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Figure legends 
 
Figure 1. The process of systematic reviews and meta-analyses. White circles represent individual 
papers containing different sets of data (circles, squares, hexagons, stars). Data that are relevant for 
the study (represented as blue squares) are extracted and combined in a meta-analysis. 
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Appendix 
 
 
Animal study search string for Pubmed 12 
 
(“animal experimentation”[MeSH Terms] OR “models, animal”[MeSH Terms] OR 
“invertebrates”[MeSH Terms] OR “Animals”[Mesh:noexp] OR “animal population groups”[MeSH 
Terms] OR “chordata”[MeSH Terms:noexp] OR “chordata, nonvertebrate”[MeSH Terms] OR 
“vertebrates”[MeSH Terms:noexp] OR “amphibians”[MeSH Terms] OR “birds”[MeSH Terms] OR 
“fishes”[MeSH Terms] OR “reptiles”[MeSH Terms] OR “mammals”[MeSH Terms:noexp] OR 
“primates”[MeSH Terms:noexp] OR “artiodactyla”[MeSH Terms] OR “carnivora”[MeSH Terms] OR 
“cetacea”[MeSH Terms] OR “chiroptera”[MeSH Terms] OR “elephants”[MeSH Terms] OR 
“hyraxes”[MeSH Terms] OR “insectivora”[MeSH Terms] OR “lagomorpha”[MeSH Terms] OR 
“marsupialia”[MeSH Terms] OR “monotremata”[MeSH Terms] OR “perissodactyla”[MeSH Terms] 
OR “rodentia”[MeSH Terms] OR “scandentia”[MeSH Terms] OR “sirenia”[MeSH Terms] OR 
“xenarthra”[MeSH Terms] OR “haplorhini”[MeSH Terms:noexp] OR “strepsirhini”[MeSH Terms] OR 
“platyrrhini”[MeSH Terms] OR “tarsii”[MeSH Terms] OR “catarrhini”[MeSH Terms:noexp] OR 
“cercopithecidae”[MeSH Terms] OR “hylobatidae”[MeSH Terms] OR “hominidae”[MeSH 
Terms:noexp] OR “gorilla gorilla”[MeSH Terms] OR “pan paniscus”[MeSH Terms] OR “pan 
troglodytes”[MeSH Terms] OR “pongo pygmaeus”[MeSH Terms]) OR ((animals[tiab] OR 
animal[tiab] OR mice[Tiab] OR mus[Tiab] OR mouse[Tiab] OR murine[Tiab] OR woodmouse[tiab] 
OR rats[Tiab] OR rat[Tiab] OR murinae[Tiab] OR muridae[Tiab] OR cottonrat[tiab] OR 
cottonrats[tiab] OR hamster[tiab] OR hamsters[tiab] OR cricetinae[tiab] OR rodentia[Tiab] OR 
rodent[Tiab] OR rodents[Tiab] OR pigs[Tiab] OR pig[Tiab] OR swine[tiab] OR swines[tiab] OR 
piglets[tiab] OR piglet[tiab] OR boar[tiab] OR boars[tiab] OR “sus scrofa”[tiab] OR ferrets[tiab] OR 
ferret[tiab] OR polecat[tiab] OR polecats[tiab] OR “mustela putorius”[tiab] OR “guinea pigs”[Tiab] 
OR “guinea pig”[Tiab] OR cavia[Tiab] OR callithrix[Tiab] OR marmoset[Tiab] OR marmosets[Tiab] 
OR cebuella[Tiab] OR hapale[Tiab] OR octodon[Tiab] OR chinchilla[Tiab] OR chinchillas[Tiab] OR 
gerbillinae[Tiab] OR gerbil[Tiab] OR gerbils[Tiab] OR jird[Tiab] OR jirds[Tiab] OR merione[Tiab] 
OR meriones[Tiab] OR rabbits[Tiab] OR rabbit[Tiab] OR hares[Tiab] OR hare[Tiab] OR diptera[Tiab] 
OR flies[Tiab] OR fly[Tiab] OR dipteral[Tiab] OR drosophila[Tiab] OR drosophilidae[Tiab] OR 
cats[Tiab] OR cat[Tiab] OR carus[Tiab] OR felis[Tiab] OR nematoda[Tiab] OR nematode[Tiab] OR 
nematodes[Tiab] OR sipunculida[Tiab] OR dogs[Tiab] OR dog[Tiab] OR canine[Tiab] OR 
canines[Tiab] OR canis[Tiab] OR sheep[Tiab] OR sheeps[Tiab] OR mouflon[Tiab] OR 
mouflons[Tiab] OR ovis[Tiab] OR goats[Tiab] OR goat[Tiab] OR capra[Tiab] OR capras[Tiab] OR 
rupicapra[Tiab] OR rupicapras[Tiab] OR chamois[Tiab] OR haplorhini[Tiab] OR monkey[Tiab] OR 
monkeys[Tiab] OR anthropoidea[Tiab] OR anthropoids[Tiab] OR saguinus[Tiab] OR tamarin[Tiab] 
OR tamarins[Tiab] OR leontopithecus[Tiab] OR hominidae[Tiab] OR ape[Tiab] OR apes[Tiab] OR 
“pan paniscus”[Tiab] OR bonobo[Tiab] OR bonobos[Tiab] OR “pan troglodytes”[Tiab] OR 
gibbon[Tiab] OR gibbons[Tiab] OR siamang[Tiab] OR siamangs[Tiab] OR nomascus[Tiab] OR 
symphalangus[Tiab] OR chimpanzee[Tiab] OR chimpanzees[Tiab] OR prosimian[Tiab] OR 
prosimians[Tiab] OR “bush baby”[Tiab] OR bush babies[Tiab] OR galagos[Tiab] OR galago[Tiab] OR 
pongidae[Tiab] OR gorilla[Tiab] OR gorillas[Tiab] OR “pongo pygmaeus”[Tiab] OR orangutan[Tiab] 
OR orangutans[Tiab] OR lemur[Tiab] OR lemurs[Tiab] OR lemuridae[Tiab] OR horse[Tiab] OR 
horses[Tiab] OR equus[Tiab] OR cow[Tiab] OR calf[Tiab] OR bull[Tiab] OR chicken[Tiab] OR 
chickens[Tiab] OR gallus[Tiab] OR quail[Tiab] OR bird[Tiab] OR birds[Tiab] OR quails[Tiab] OR 
poultry[Tiab] OR poultries[Tiab] OR fowl[Tiab] OR fowls[Tiab] OR reptile[Tiab] OR reptilia[Tiab] 
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OR reptiles[Tiab] OR snakes[Tiab] OR snake[Tiab] OR lizard[Tiab] OR lizards[Tiab] OR 
alligator[Tiab] OR alligators[Tiab] OR crocodile[Tiab] OR crocodiles[Tiab] OR turtle[Tiab] OR 
turtles[Tiab] OR amphibian[Tiab] OR amphibians[Tiab] OR amphibia[Tiab] OR frog[Tiab] OR 
frogs[Tiab] OR bombina[Tiab] OR salientia[Tiab] OR toad[Tiab] OR toads[Tiab] OR “epidalea 
calamita”[Tiab] OR salamander[Tiab] OR salamanders[Tiab] OR eel[Tiab] OR eels[Tiab] OR 
fish[Tiab] OR fishes[Tiab] OR pisces[Tiab] OR catfish[Tiab] OR catfishes[Tiab] OR 
siluriformes[Tiab] OR arius[Tiab] OR heteropneustes[Tiab] OR sheatfish[Tiab] OR perch[Tiab] OR 
perches[Tiab] OR percidae[Tiab] OR perca[Tiab] OR trout[Tiab] OR trouts[Tiab] OR char[Tiab] OR 
chars[Tiab] OR salvelinus[Tiab] OR minnow[Tiab] OR cyprinidae[Tiab] OR carps[Tiab] OR 
carp[Tiab] OR zebrafish[Tiab] OR zebrafishes[Tiab] OR goldfish[Tiab] OR goldfishes[Tiab] OR 
guppy[Tiab] OR guppies[Tiab] OR chub[Tiab] OR chubs[Tiab] OR tinca[Tiab] OR barbels[Tiab] OR 
barbus[Tiab] OR pimephales[Tiab] OR promelas[Tiab] OR “poecilia reticulata”[Tiab] OR mullet[Tiab] 
OR mullets[Tiab] OR eel[Tiab] OR eels[Tiab] OR seahorse[Tiab] OR seahorses[Tiab] OR mugil 
curema[Tiab] OR atlantic cod[Tiab] OR shark[Tiab] OR sharks[Tiab] OR catshark[Tiab] OR 
anguilla[Tiab] OR salmonid[Tiab] OR salmonids[Tiab] OR whitefish[Tiab] OR whitefishes[Tiab] OR 
salmon[Tiab] OR salmons[Tiab] OR sole[Tiab] OR solea[Tiab] OR lamprey[Tiab] OR lampreys[Tiab] 
OR pumpkinseed[Tiab] OR sunfish[Tiab] OR sunfishes[Tiab] OR tilapia[Tiab] OR tilapias[Tiab] OR 
turbot[Tiab] OR turbots[Tiab] OR flatfish[Tiab] OR flatfishes[Tiab] OR sciuridae[Tiab] OR 
squirrel[Tiab] OR squirrels[Tiab] OR chipmunk[Tiab] OR chipmunks[Tiab] OR suslik[Tiab] OR 
susliks[Tiab] OR vole[Tiab] OR voles[Tiab] OR lemming[Tiab] OR lemmings[Tiab] OR 
muskrat[Tiab] OR muskrats[Tiab] OR lemmus[Tiab] OR otter[Tiab] OR otters[Tiab] OR marten[Tiab] 
OR martens[Tiab] OR martes[Tiab] OR weasel[Tiab] OR badger[Tiab] OR badgers[Tiab] OR 
ermine[Tiab] OR mink[Tiab] OR minks[Tiab] OR sable[Tiab] OR sables[Tiab] OR gulo[Tiab] OR 
gulos[Tiab] OR wolverine[Tiab] OR wolverines[Tiab] OR mustela[Tiab] OR llama[Tiab] OR 
llamas[Tiab] OR alpaca[Tiab] OR alpacas[Tiab] OR camelid[Tiab] OR camelids[Tiab] OR 
guanaco[Tiab] OR guanacos[Tiab] OR chiroptera[Tiab] OR chiropteras[Tiab] OR bat[Tiab] OR 
bats[Tiab] OR fox[Tiab] OR foxes[Tiab] OR iguana[Tiab] OR iguanas[Tiab] OR xenopus laevis[Tiab] 
OR parakeet[Tiab] OR parakeets[Tiab] OR parrot[Tiab] OR parrots[Tiab] OR donkey[Tiab] OR 
donkeys[Tiab] OR mule[Tiab] OR mules[Tiab] OR zebra[Tiab] OR zebras[Tiab] OR shrew[Tiab] OR 
shrews[Tiab] OR bison[Tiab] OR bisons[Tiab] OR buffalo[Tiab] OR buffaloes[Tiab] OR deer[Tiab] 
OR deers[Tiab] OR bear[Tiab] OR bears[Tiab] OR panda[Tiab] OR pandas[Tiab] OR “wild 
hog”[Tiab] OR “wild boar”[Tiab] OR fitchew[Tiab] OR fitch[Tiab] OR beaver[Tiab] OR 
beavers[Tiab] OR jerboa[Tiab] OR jerboas[Tiab] OR capybara[Tiab] OR capybaras[Tiab]) NOT 
medline[sb]) 
 
 
Animal study search string for Embase 13 
 
exp animal experiment/ or exp animal model/ or exp experimental animal/ or exp transgenic animal/ or 
exp male animal/ or exp female animal/ or exp juvenile animal/ OR animal/ OR chordata/ OR 
vertebrate/ OR tetrapod/ OR exp fish/ OR amniote/ OR exp amphibia/ OR mammal/ OR exp reptile/ 
OR exp sauropsid/ OR therian/OR exp monotremate/ OR placental mammals/ OR exp marsupial/ OR 
Euarchontoglires/ OR exp Afrotheria/ OR exp Boreoeutheria/ OR exp Laurasiatheria/ OR exp 
Xenarthra/ OR primate/ OR exp Dermoptera/ OR exp Glires/ OR exp Scandentia/ OR Haplorhini/ OR 
exp prosimian/ OR simian/ OR exp tarsiiform/ OR Catarrhini/ OR exp Platyrrhini/ OR ape/ OR exp 
Cercopithecidae/ OR hominid/ OR exp hylobatidae/ OR exp chimpanzee/ OR exp gorilla/ OR exp 
orang utan/ OR (animal OR animals OR pisces OR fish OR fishes OR catfish OR catfishes OR 
sheatfish OR silurus OR arius OR heteropneustes OR clarias OR gariepinus OR fathead minnow OR 
  25 
fathead minnows OR pimephales OR promelas OR cichlidae OR trout OR trouts OR char OR chars OR 
salvelinus OR salmo OR oncorhynchus OR guppy OR guppies OR millionfish OR poecilia OR 
goldfish OR goldfishes OR carassius OR auratus OR mullet OR mullets OR mugil OR curema OR 
shark OR sharks OR cod OR cods OR gadus OR morhua OR carp OR carps OR cyprinus OR carpio 
OR killifish OR eel OR eels OR anguilla OR zander OR sander OR lucioperca OR stizostedion OR 
turbot OR turbots OR psetta OR flatfish OR flatfishes OR plaice OR pleuronectes OR platessa OR 
tilapia OR tilapias OR oreochromis OR sarotherodon OR common sole OR dover sole OR solea OR 
zebrafish OR zebrafishes OR danio OR rerio OR seabass OR dicentrarchus OR labrax OR morone OR 
lamprey OR lampreys OR petromyzon OR pumpkinseed OR pumpkinseeds OR lepomis OR gibbosus 
OR herring OR clupea OR harengus OR amphibia OR amphibian OR amphibians OR anura OR 
salientia OR frog OR frogs OR rana OR toad OR toads OR bufo OR xenopus OR laevis OR bombina 
OR epidalea OR calamita OR salamander OR salamanders OR newt OR newts OR triturus OR reptilia 
OR reptile OR reptiles OR bearded dragon OR pogona OR vitticeps OR iguana OR iguanas OR lizard 
OR lizards OR anguis fragilis OR turtle OR turtles OR snakes OR snake OR aves OR bird OR birds 
OR quail OR quails OR coturnix OR bobwhite OR colinus OR virginianus OR poultry OR poultries 
OR fowl OR fowls OR chicken OR chickens OR gallus OR zebra finch OR taeniopygia OR guttata OR 
canary OR canaries OR serinus OR canaria OR parakeet OR parakeets OR grasskeet OR parrot OR 
parrots OR psittacine OR psittacines OR shelduck OR tadorna OR goose OR geese OR branta OR 
leucopsis OR woodlark OR lullula OR flycatcher OR ficedula OR hypoleuca OR dove OR doves OR 
geopelia OR cuneata OR duck OR ducks OR greylag OR graylag OR anser OR harrier OR circus 
pygargus OR red knot OR great knot OR calidris OR canutus OR godwit OR limosa OR lapponica OR 
meleagris OR gallopavo OR jackdaw OR corvus OR monedula OR ruff OR philomachus OR pugnax 
OR lapwing OR peewit OR plover OR vanellus OR swan OR cygnus OR columbianus OR bewickii 
OR gull OR chroicocephalus OR ridibundus OR albifrons OR great tit OR parus OR aythya OR 
fuligula OR streptopelia OR risoria OR spoonbill OR platalea OR leucorodia OR blackbird OR turdus 
OR merula OR blue tit OR cyanistes OR pigeon OR pigeons OR columba OR pintail OR anas OR 
starling OR sturnus OR owl OR athene noctua OR pochard OR ferina OR cockatiel OR nymphicus OR 
hollandicus OR skylark OR alauda OR tern OR sterna OR teal OR crecca OR oystercatcher OR 
haematopus OR ostralegus OR shrew OR shrews OR sorex OR araneus OR crocidura OR russula OR 
european mole OR talpa OR chiroptera OR bat OR bats OR eptesicus OR serotinus OR myotis OR 
dasycneme OR daubentonii OR pipistrelle OR pipistrellus OR cat OR cats OR felis OR catus OR feline 
OR dog OR dogs OR canis OR canine OR canines OR otter OR otters OR lutra OR badger OR badgers 
OR meles OR fitchew OR fitch OR foumart or foulmart OR ferrets OR ferret OR polecat OR polecats 
OR mustela OR putorius OR weasel OR weasels OR fox OR foxes OR vulpes OR common seal OR 
phoca OR vitulina OR grey seal OR halichoerus OR horse OR horses OR equus OR equine OR 
equidae OR donkey OR donkeys OR mule OR mules OR pig OR pigs OR swine OR swines OR hog 
OR hogs OR boar OR boars OR porcine OR piglet OR piglets OR sus OR scrofa OR llama OR llamas 
OR lama OR glama OR deer OR deers OR cervus OR elaphus OR cow OR cows OR bos taurus OR 
bos indicus OR bovine OR bull OR bulls OR cattle OR bison OR bisons OR sheep OR sheeps OR ovis 
aries OR ovine OR lamb OR lambs OR mouflon OR mouflons OR goat OR goats OR capra OR 
caprine OR chamois OR rupicapra OR leporidae OR lagomorpha OR lagomorph OR rabbit OR rabbits 
OR oryctolagus OR cuniculus OR laprine OR hares OR lepus OR rodentia OR rodent OR rodents OR 
murinae OR mouse OR mice OR mus OR musculus OR murine OR woodmouse OR apodemus OR rat 
OR rats OR rattus OR norvegicus OR guinea pig OR guinea pigs OR cavia OR porcellus OR hamster 
OR hamsters OR mesocricetus OR cricetulus OR cricetus OR gerbil OR gerbils OR jird OR jirds OR 
meriones OR unguiculatus OR jerboa OR jerboas OR jaculus OR chinchilla OR chinchillas OR beaver 
OR beavers OR castor fiber OR castor canadensis OR sciuridae OR squirrel OR squirrels OR sciurus 
OR chipmunk OR chipmunks OR marmot OR marmots OR marmota OR suslik OR susliks OR 
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spermophilus OR cynomys OR cottonrat OR cottonrats OR sigmodon OR vole OR voles OR microtus 
OR myodes OR glareolus OR primate OR primates OR prosimian OR prosimians OR lemur OR 
lemurs OR lemuridae OR loris OR bush baby OR bush babies OR bushbaby OR bushbabies OR galago 
OR galagos OR anthropoidea OR anthropoids OR simian OR simians OR monkey OR monkeys OR 
marmoset OR marmosets OR callithrix OR cebuella OR tamarin OR tamarins OR saguinus OR 
leontopithecus OR squirrel monkey OR squirrel monkeys OR saimiri OR night monkey OR night 
monkeys OR owl monkey OR owl monkeys OR douroucoulis OR aotus OR spider monkey OR spider 
monkeys OR ateles OR baboon OR baboons OR papio OR rhesus monkey OR macaque OR macaca 
OR mulatta OR cynomolgus OR fascicularis OR green monkey OR green monkeys OR chlorocebus 
OR vervet OR vervets OR pygerythrus OR hominoidea OR ape OR apes OR hylobatidae OR gibbon 
OR gibbons OR siamang OR siamangs OR nomascus OR symphalangus OR hominidae OR orangutan 
OR orangutans OR pongo OR chimpanzee OR chimpanzees OR pan troglodytes OR bonobo OR 
bonobos OR pan paniscus OR gorilla OR gorillas OR troglodytes).ti,ab. 
 
 
